Alpha Tau to Host Conference Call for Interim Glioblastoma Trial Results
DRTS has more than doubled off its 52-week low of $2.57.
Summary
Alpha Tau Medical announced it will host a conference call to discuss interim clinical data from the first three patients in its U.S. REGAIN trial for recurrent glioblastoma, signaling upcoming insights into its Alpha DaRT therapy for this challenging cancer.
Key Events · Product Development and Regulatory · DRTS
-
Conference Call Scheduled
Alpha Tau Medical will host a conference call and webcast on Monday, May 11, 2026, at 8:30 AM ET.
-
Focus on Glioblastoma Trial
The call will discuss interim clinical data from the first three patients treated in its U.S. REGAIN trial for recurrent glioblastoma (GBM).
-
Interim Data from Early Patients
The REGAIN study aims to evaluate the feasibility and safety of the Alpha DaRT treatment in up to ten U.S. patients with recurrent glioblastoma not amenable to surgical resection.
Analysis · DRTS · Industrial Applications And Services
Alpha Tau Medical's announcement of a conference call to discuss interim clinical data from its U.S. REGAIN trial for recurrent glioblastoma is a significant event. Glioblastoma is an aggressive and difficult-to-treat brain cancer with high unmet medical need, making any progress in treatment highly impactful. While this filing only announces the call, the decision to host a dedicated event for interim results from the first three patients suggests the company anticipates sharing encouraging data. This follows a series of positive clinical updates from Alpha Tau, indicating active development and potential for its Alpha DaRT therapy in challenging oncology indications. Investors will closely watch the upcoming call for insights into the therapy's safety and efficacy in this critical patient population.
At the time of this filing, DRTS was trading at $7.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $690.9M. The 52-week trading range was $2.57 to $9.07. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.